Simpson Thacher Expands Secondaries Team With Hire of Ed Ford and Sacha Gofton-Salmond
13.2.2023 19:00:00 EET | Business Wire | Press release
Simpson Thacher & Bartlett LLP announced today that Ed Ford and Sacha Gofton-Salmond will join the Firm as Partners in the London office, where they will focus on secondaries transactions.
“Ed and Sacha are highly regarded in the secondaries space, having built up a market leading practice in recent years and will add depth to our renowned Private Funds and Fund Transactions Practices, further bolstering our ability to advise sponsors and investors on liquidity solutions that provide additional flexibility to address an ever-changing market,” said Alden Millard, Chair of Simpson Thacher’s Executive Committee. “We are thrilled to welcome them to Simpson Thacher.”
“Simpson Thacher has developed a robust presence in the fund transactional space, which was strengthened by the addition of Lauren King in New York in 2021,” said Michael Wolitzer, Head of Simpson Thacher’s Investment Funds Practice. “With the addition of Ed and Sacha, the Firm is further augmenting its capabilities to provide sponsor clients and other industry participants with multidisciplinary secondaries solutions around the globe.”
Ed and Sacha both specialize in advising clients on the structuring and negotiation of highly complex secondary market solutions, ranging from GP- and LP-led secondary transactions to NAV financings, preferred equity financings and other structured secondary transactions. Both lawyers join the Firm from Travers Smith.
“Ed and Sacha are both incredibly talented lawyers that have the versatile experience and commercial creativity that is the hallmark of Simpson Thacher’s Investment Funds Practice,” said Jason Glover, Head of Simpson Thacher’s London office and the Firm’s European Funds team. “We have admired Ed’s and Sacha’s respective success in the secondaries space for some time and believe that their arrival at Simpson Thacher will enhance our existing secondaries transaction platform in London. Such hires mark the latest step in enhancing our private funds offering and solidifying our position as the global investment funds law firm of choice.”
Simpson Thacher’s Fund Transactions Practice advises on the full breadth of secondaries transactions, as well as complex control and minority-stakes transactions involving alternative asset managers and preferred and structured financings for funds, their management companies and other industry participants. Drawing upon the Firm’s more than 40 years of experience in the private equity industry, the global team comprises funds, mergers and acquisitions, finance, tax and other lawyers who provide commercially-driven, comprehensive transactional advice for the world’s most sophisticated sponsors. The multidisciplinary team offers deep market knowledge and creative, tailored advice on transactions, including traditional and synthetic secondaries deals, GP-led restructurings, preferred equity transactions and other liquidity solutions.
ABOUT SIMPSON THACHER
Simpson Thacher & Bartlett LLP (www.simpsonthacher.com) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Brussels, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005393/en/
Contact information
Arielle Katz
Communications Manager
mediainquiries@stblaw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom